Skip to main content

Advertisement

SpringerLink
Log in

Measurements of the strontium plasma clearance rate in patients receiving 89Sr radionuclide therapy

  • Published:
European Journal of Nuclear Medicine Aims and scope Submit manuscript

Abstract

The total strontium plasma clearance rate due to excretion through the kidneys and gut has an imporant influence on the absorbed does delivered to skeletal metastases and red bone marrow in patients receiving 89Sr radionuclide therapy for disseminated prostatic carcinoma. Although a measurement of the renal strontium plasma clearance rate may readily be obtained through a 24-h urine collection, little information is available on the correlation between renal and total clearances. We describe a method of determining total strontium plasma clearance rate from whole body counter measurements of total body strontium retention and measurements of plasma strontium concentration following administration of a 85Sr tracer dose at the time of 89Sr therapy. Amongst the 26 patients whom we studied, the total clearance rate varied from 1.2–15.0 l/day, renal clearance rate from 0.1–11.5 l/day, and the mean gut clearance rate was 2.0 l/day. A close correlation was found between total and renal clearance, with the renal component accounting for 96% of the variance in total strontium plasma clearance. A weak collection may exist between gut and renal clearance.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Blake GM, Gray JM, Zivanovic MA, McEwan AJ, Fleming JS, Ackery DM (1987) Strontium-89 radionuclide therapy: a dosimetric study using impulse response function analysis. Br J Radiol 60:685–692

    Google Scholar 

  • Blake GM, Zivanovic MA, Blaquiere RM, Fine DR, McEwan AJ, Ackery DM (1988) Sr-89 therapy: measurement of absorbed dose to skeletal metastases. J Nucl Med 29:549–557

    Google Scholar 

  • Blake GM, Wood JF, Wood PJ, Zivanovic MA, Lewington VJ (1989) Sr-89 therapy: strontium plasma clearance in disseminated prostatic carcinoma. Eur J Nucl Med 15:49–54

    Google Scholar 

  • Dudley RA, ben Haim A (1968) Comparison of techniques for whole-body counting of gamma ray emitting nuclides with NaI(Tl) detectors 1: Point sources in phantoms. Phys Med Biol 13:181–193

    Google Scholar 

  • Firusian N, Mellin P, Schmidt CG (1976) Results of strontium-89 therapy in patients with carcinoma of the prostate and incurable pain from bone metastases: a preliminary report. J Urol 116: 764–768

    Google Scholar 

  • Harrison GE, Raymond WHA, Tretheway HC (1955) The metabolism of strontium in man. Clin Sci 14:681–695

    Google Scholar 

  • Harrison GE, Sutton A (1967) Ratio of the faecal to urinary clearance of strontium in man. In: Lenihan JMA, Loutit JF, Martin JH (eds) Strontium Metabolism. Academic Press, London, pp 161–166

    Google Scholar 

  • ICRP (1975) ICRP Publication 23: Report of the task group on reference man. Pergamon Press, Oxford

    Google Scholar 

  • Kloiber R, Molnar CP, Barnes M (1987) Sr-89 therapy for metastatic bone disease: scintigraphic and radiographic follow-up. Radiology 163:719–723

    Google Scholar 

  • Laing AH (1987) Strontium-89 therapy for skeletal metastases. Br J Radiol (abstr.) 60:732

    Google Scholar 

  • Lewington VJ, Zivanovic MA, Blake GM, Buchanan RB, Ackery DM (1988) Treatment of bone pain in disseminated prostatic carcinoma using strontium-89. Nucl Med Commun (abstr.) 9:179–180

    Google Scholar 

  • Marshall JH, Lloyd EL, Rundo J, Liniecki J, Marroti G, Mays CW, Sissons HA, Snyder WS (1973) Alkaline earth metabolism in adult man. Health Physics 24:125–221

    Google Scholar 

  • Pecher C (1942) Biological investigations with radioactive calcium and strontium: preliminary report on the use of radioactive strontium in the treatment of bone cancer. University of California Publications in Pharmacology 11:117–149

    Google Scholar 

  • Robinson RG (1986) Radionuclides for the alleviation of bone pain in advanced malignancy. Clin Oncol 5:39–49

    Google Scholar 

  • Silberstein EB, Williams C (1985) Strontium-89 therapy for the pain of osseous metastases. J Nucl Med 26:345–348

    Google Scholar 

  • Urwin GH, Percival RC, Galloway J, Guilland-Cumming DF, Lawson-Matthew PJ, Williams JL, Kanis JA (1986) Endocrinology of disseminated prostatic carcinoma. Bone (abstr) 7:305

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Guy's Hospital, London Bridge, SE1 9RT, London, UK

    Glen M. Blake

  2. Department of Nuclear Medicine, Southampton General Hospital, Southampton, UK

    Maureen A. Zivanovic & Valerie J. Lewington

Authors
  1. Glen M. Blake
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maureen A. Zivanovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Valerie J. Lewington
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Blake, G.M., Zivanovic, M.A. & Lewington, V.J. Measurements of the strontium plasma clearance rate in patients receiving 89Sr radionuclide therapy. Eur J Nucl Med 15, 780–783 (1989). https://doi.org/10.1007/BF00255497

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00255497

Key words

Search

Navigation